Free tool
FAERS Monitor: Monistat 3 Combination Pack
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021261 or its brand name (Monistat 3 Combination Pack, Miconazole Nitrate). Reports on generic versions are filed under their own applications.
Reports
2,640
Serious
800
30% of reports
Hospitalization
329
Death reported
86
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vulvovaginal burning sensation742
- vulvovaginal pain525
- drug ineffective313
- vulvovaginal pruritus253
- vaginal haemorrhage235
- vulvovaginal discomfort192
- condition aggravated179
- vulvovaginal swelling155
- pain102
- pruritus74
- abdominal pain71
- hypersensitivity69
- burning sensation66
- off label use66
- drug interaction62
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 20 |
| 2006 | 20 |
| 2007 | 13 |
| 2008 | 36 |
| 2009 | 66 |
| 2010 | 42 |
| 2011 | 46 |
| 2012 | 73 |
| 2013 | 16 |
| 2014 | 23 |
| 2015 | 31 |
| 2016 | 122 |
| 2017 | 112 |
| 2018 | 202 |
| 2019 | 196 |
| 2020 | 207 |
| 2021 | 264 |
| 2022 | 243 |
| 2023 | 162 |
| 2024 | 222 |
| 2025 | 266 |
| 2026 | 244 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,519 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vulvovaginal burning sensationSignal | 742 | 1102.2 | 1031.2 | 716,469 |
| vulvovaginal painSignal | 525 | 974.3 | 897.4 | 454,098 |
| vulvovaginal swellingSignal | 155 | 738.8 | 629.5 | 103,853 |
| vulvovaginal pruritusSignal | 253 | 418.8 | 371.3 | 99,820 |
| vulvovaginal discomfortSignal | 192 | 361.8 | 314.7 | 65,748 |
| vaginal haemorrhageSignal | 235 | 43.4 | 38.4 | 9,651 |
| burning sensationSignal | 66 | 7.5 | 5.9 | 367 |
| condition aggravatedSignal | 179 | 4.7 | 4.1 | 524 |
| drug interactionSignal | 62 | 3.1 | 2.4 | 88 |
| hypersensitivitySignal | 69 | 3.0 | 2.3 | 88 |
| abdominal painSignal | 71 | 2.4 | 1.9 | 59 |
| drug ineffective | 313 | 1.9 | 1.7 | 140 |
| pruritus | 74 | 1.5 | 1.2 | 13 |
| pain | 102 | 1.3 | 1.1 | 8 |
| off label use | 66 | 0.6 | 0.5 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.